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Aim: To determine frequency of tumors with immunohistochemical markers of cancer stem cells (CSC) CD44+/CD24− in patients 
with breast cancer (BC) of different molecular subtype and to evaluate their prognostic value. Object: Surgical material of 132 pa-
tients with BC stage I–II, age from 23 to 75 years, mean age — 50.2 ± 3.1 years was studied. Methods: Clinical, immunohisto-
chemical (expression CD44+/CD24−), morphological, statistical. Results: BC is characterized by heterogeneity of molecular 
subtypes and expression of markers (CD44+/CD24−). Immunohistochemical study of expression of CSC markers in surgical 
material has detected their expression in 34 (25.4%) patients with BC of different molecular subtypes. The highest frequency of cells 
with expression of CSC marker was observed in patients with basal molecular subtype (44.8% patients). Most of BC patients with 
phenotype CD44+/CD24 had stage I of tumor process (34.3%). Statistical processing of data has showen that Yule colligation 
coefficient equaled 0.28 (р > 0.05) that argues poor correlation between stage of tumor process and number of tumors with positive 
expression of CSC markers. Statistical processing of data has showen high correlation between presence of cells with expression 
of CSC markers and metastases of BC in regional lymph nodes (Yule colligation coefficient equals 0.943; р < 0.5). Difference 
in overall survival of patients with BC of basal molecular subtype depending on expression of CSC CD44+/CD24− markers was 
detected. Survival of patients with basal BC was reliably higher at lack in tumors of cells with CSC markers CD44+/CD24− and, 
correspondingly, lower at presence of such cells (р < 0.05). In patients with BC of luminal (A and B), HER-2-positive subtypes, 
significant change in survival of patients depending on expression of CSC markers was not determined (р > 0.05). Conclusion: 
Significance of tumor cells with markers CD44+/CD24− within the limits of molecular subtype of BC may be additional criterion 
for advanced biological characteristic of BC, and in patients with BC of basal molecular subtype — for predictive evaluation of in-
dividual potential of tumor to aggressive clinical course.
Key Words: breast cancer, cancer stem cells, СD44+/CD24−, molecular subtype.
Breast cancer (BC) is one of the most widespread 
forms of female cancer pathology in many countries 
of the world. Dangerous situation concerning BC is ob-
served in Ukraine as well: according to updated infor-
mation of National Cancer Register of Ukraine (2012) 
BC morbidity and mortality (raw indices) are respec-
tively 72.5 and 32.2 per 100 000 of female population. 
Only 13.3% patients has received surgical treatment 
alone, while combined or complex treatment — 
68.5% [1] that evidences that the significant number 
of patients had advanced stages of BC. Treatment 
results, being not always satisfactory due to tumors’ 
chemo- and radioresistances and significant variability 
of BC clinical course [2–6], serve the basis for more 
pronounced study of BC bio logy from positions of its 
origin, growth and metastasis.
Intense molecular-biological studies have deter-
mined that BC is complicated multi-stage process 
of accumulation of structural and functional effects 
of genes, which are associated with proliferation, neo-
angiogenesis, intercellular adhesion disturbances, pe-
culiarities of microenvironment of tumor cells and their 
clonal evolution. The main result of these studies was 
the identification of BC as heterogeneous disease with 
different properties of growth and metastasis [7, 8]. 
This is confirmed by identification of different BC mo-
lecular subtypes depending on expression of estrogen 
receptors (ER), progesterone receptors (PR) and 
human epidermal growth factor type 2 (HER2/neu). 
Basing on this, the following BC subtypes were de-
termined, namely: luminal A, luminal B, basal or triple-
negative, HER2/neu-positive [9–12]. Mammologists 
are guided by these biological subtypes while treat-
ment process and evaluation of disease prognosis.
Despite widespread use of such classification 
in clinical practice, it is not always possible to predict 
precisely the clinical course of disease and tumor 
“response” to the treatment. It is due to the fact that 
BC of one histological type or even of one molecular 
subtype is characterized by different proliferative 
potential of tumor cells, adhesion disturbances, pecu-
liarities of tumor microenvironment, which altogether 
determine not only intercellular, but also intracellular 
biological heterogeneity [13–15]. Literature data con-
firm the dependence of unfavorable BC clinical course 
and prognosis from tumor biological heterogeneity, 
genetic and proteomic changes in tumor cells [16–18].
In this aspect, cancer stem cells (CSC) attract atten-
tion. According to the conception of CSC significance 
for tumor occurrence and growth, such cells possess 
specific features. Like normal stem cells, they have 
capability to grow, can self-renew and differentiate into 
various types of cells. Their specific feature is: while CSC 
division one of the daughter cells preserves properties 
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of parent cell, while cells proliferation is associated with 
CD44+/CD24− phenotype [19–21]. Cells with such 
phenotype are called tumorogenic or tumor-initiating 
cells due to the features of their proliferative potential. 
Studies on CSC have determined that biological and 
molecular heterogeneity of BC depends on the amount 
of such cells [22], their microenvironment and expression 
of certain cytokines [23]. Biological properties of these 
cells were studied on experimental cells lines in vitro [24]. 
Earlier in our studies on CSC in cell lines of BC (T47D, 
MCF-7, MDA-MB 231, MDA-MB 468) we have deter-
mined some regularities of CSC markers expression 
depending on their molecular phenotype [25].
Thus, in modern literature, both the significance 
of BC molecular phenotypes for characterization 
of BC heterogeneity and the hypothesis of intratumoral 
heterogeneity formation, in which CSC may play sig-
nificant role, are actively discussed. But CSC associa-
tion with clinical features of BC of different histological 
types, with metastasis and patients survival remains 
unclear. For this reason, the study of BC heterogeneity 
and cellular peculiarities of tumors using immunohis-
tochemical markers of CSC is relevant problem, which 
solution will promote extension of knowledge on bio-
logy of tumor growth in mammary gland and improve 
patients’ treatment.
Taking into account above-stated, the aim of this 
study was to determine the prevalence of tumors with 
immunohistochemical markers of cancer stem cell 
CD44+/CD24− in patients with BC of different molecu-
lar subtype and evaluate their prognostic significance.
MATERIALS AND METHODS
Our studies are based on retrospective analysis 
of results of examination, treatment and survival 
of 132 BC patients with I–II stages, who received 
special treatment in Kyiv City Clinical Cancer Center 
during 2005–2007. The samples of surgical mate-
rial of BC were studied. These samples were stored 
in clinical database of the Department of Antitumor 
Therapy Mechanisms of R.E. Kavetsky Institute of Ex-
perimental Pathology, Oncology and Radiobiology, 
NAS of Ukraine. The tumor stage was determined 
according to the International Tumor Classification 
(TNM, Edition 6, 2002). Histological type of tumors 
was verified on histological sections of tumors’ paraffin 
blocks (staining with hematoxylin and eosin) according 
with the WHO International Histological Classification 
(2006). Depending on clinical indications, patients 
underwent organ-saving surgeries or radical Mad-
den mastectomies, and adjuvant polychemotherapy 
(CAF or AC schemes with 21 day interval, number 
of courses varied from 4 to 6), according with the 
approved in Ukraine Standards of BC Patients’ Treat-
ment. Postoperative radiation therapy was performed 
on postoperative scar, axillary, parasternal and supra-
clavicular regions; the single focal dose was 2 Gy, and 
the total focal dose — 40 Gy.
For evaluation of BC molecular subtype we per-
formed the immunohistochemical studies of expres-
sion of three molecular markers that are widely used 
nowadays for immunohistochemical BC diagnosis: ER, 
PR, Her2/neu. We used histological sections (4 micron 
thickness) of paraffin blocks. The following monoclonal 
antibodies were used: antiER — clone 1D5, antiPR- 
clone PgR636, antiHER/2neu — clone c-erbB-2 (Dako 
Cytomation, Denmark). The number of cells with posi-
tive markers expression were determined taking into 
account the level of immunohistochemical reaction: 
“+++” — strong, “++” — moderate, “+” — low, “0” — 
lack of expression. On the parallel paraffin sections the 
immunohistochemical study of CD24 and CD44 expres-
sion in tumor cells were carried out. As primary antibo-
dies, monoclonal antibodies specific to CD24 (clone 
SN3b, ThermoScientific, USA) and to CD44 (CD44/
HCAM,  clone 156–3C11, Diagnostic BioSystems, USA) 
were used in dilutions according to the manufacturer 
guideline. The number of immunopositive tumor cells 
more than 10% was taken as positive marker expres-
sion. For visualization of the results of all immunohisto-
chemical reactions EnVision system (Dako LSAB2 sys-
tem, Denmark) was used according to the manufac-
turer guidelines; histological sections were stained with 
Mayer’s hematoxylin. Results of immunohistochemical 
reactions were analyzed using optic microscope XSP-
137-BP, JNOEC, magnification × 200–400.
Statistic processing of the obtained results was car-
ried out using methods of variation statistics by program 
Statistica v. 6.0. For evaluation of correlation between 
expression of studied markers and clinical and patho-
logical features of BC, we used the Pearson coefficient 
of mutual conjugation (c), Yule coefficient of associa-
tion, Cox regression analysis. Evaluation of survival was 
carried out using Kaplan — Meier method starting from 
the date of treatment beginning, using log-rank test. 
Differences were considered significant at p ≤ 0.05.
RESULTS AND DISCUSSION
General clinical description of 132 BC patients 
with stage I–II is presented in the Table 1. The number 
of BC patients with stage I was 26.5%, with stage II — 
73.5%. Patients’ age was varied from 23 to 75 years, 
mean age was 50.2 ± 3.1 years. The majority of pa-
tients were in age interval 41–70 (Fig. 1, Table 1).
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Fig. 1. Distribution of BC patients with stage I–II by age
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Table 1. General clinical description of BC patients with stage I–II
Index Number of patientsn %
Total number of patients 132 100
Patients age (years)
Mean 50.2 ± 3.1
Age variation 23–75
Menstrual function
Preserved 47 35.6
Menopause 85 64.4
BC stage (after TNM)
Stage І 35 26.5
Stage II 97 73.5
Metastases in regional lymph nodes (category N)
N0 95 72.0
N1–3 37 28.0
Distant metastases (category М)
М0 132 100.0
Morphology of BC
Infiltrative ductal carcinoma 92 69.7
Infiltrative lobular carcinoma 40 30.3
Differentiation grade
G1(high) 38 28.8
G2 (moderate) 64 48.5
G3 (low) 30 22.7
Molecular subtype
Luminal А: ER+PR+HER2/neu− 54 40.9
Luminal B: ER+PR+HER2/neu+ 32 24.2
Basal (triple negative): ER−PR−HER2/neu− 29 22.0
Hеr2/neu-positive:
ER−PR−HER2/neu+ 17 12.9
According to the results of complex examination 
of patients (X-ray, ultrasound, etc.), metastases in re-
gional lymph nodes (N1–3) were detected in 28.0% 
cases, distant metastases were not detected. Mor-
phological study has determined infiltrating ductal BC 
(69.7%) more often, than lobular BC (30.3%). More 
often moderate differentiation of BC (48.5%) as com-
pared with high and low differentiation (28.8 and 
22.7%, correspondingly) was observed.
Analysis of the results of immunohistochemical 
study of ER, PR and Her2/neu expressions evidenced 
luminal A subtype in 40.9% cases, luminal B subtype — 
in 24.2%, basal subtype — in 22.0%, and Her2/neu-
positive subtype — in 12.9% cases (Table 1).
More detailed clinical and pathomorphological 
description of tumor process in BC patients depend-
ing on molecular subtype of BC is shown in Table 2. 
Distribution of patients by mean age has not detected 
significant difference (p > 0.05). Most patients with 
luminal A, basal and Her2/neu-positive molecular sub-
types (70.4–72.4%) were menopausal, while among 
patients with luminal B subtype such patients were 
43.8%. In all molecular subtypes, mostly stage II was 
diagnosed, especially in patients with luminal A (83.4%) 
and basal (82.8%) subtypes, while in patients with 
Her2/neu-positive and luminal B subtypes, stage II was 
in 53.0 і 59.4% cases, respectively. Frequency of me-
tastasis in regional lymph nodes was significantly lower 
in BC patients with both luminal subtypes.
In patients with basal and Her2/neu-positive sub-
types the number of patients without metastases and 
with metastases was almost the same: basal subtype 
(51.7 and 48.3%, respectively) and Her2/neu-positive 
subtype (52.9 and 47.1%, respectively). Irrespectively 
of tumor molecular subtype, ductal carcinoma prevailed 
in all patients, varying from 55.5% in luminal A subtype 
to 79.3% in basal (triple negative) subtype.
Table 2. Distribution of BC patients with different molecular subtypes ac-
cording to clinical data
Indices
Molecular subtype
Luminal А
n = 54 
(100%)
Luminal B
n = 32 
(100%)
Basal
n = 29 
(100%)
Hеr2/neu- 
positive
n = 17 
(100%)
n % n % n % n %
Mean age, years 51.3 ± 4.7 46.8 ± 2.5 48.1 ± 1.8 50.6 ± 4.1
Reproductive period, n = 47
Menopausal period, n = 85
16
38
29.6
70.4
18
14
56.2
43.8
8
21
27.6
72.4
5
12
29.4
70.6
Stage
Stage І, n = 35
Stage ІІ, n = 97
9
45
16.6
83.4
13
19
40.6
59.4
5
24
17.2
82.8
8
9
47.0
53.0
Metastases in lymph nodes
No metastases, N0, n = 95 45 83.3 26 81.2 15 51.7 9 52.9
Metastases in regional 
lymph nodes, N1–3, n = 37 9 16.7 6 18.8 14 48.3 8 47.1
Histological subtypes
Infiltrative ductal carcino-
ma, n = 92 30 55.5 25 78.1 23 79.3 14 82.3
Infiltrative lobular carcino-
ma, n = 40 24 44.5 7 11.9 6 20.7 3 17.7
Differentiation grade
High, n = 38 18 33.3 10 31.3 7 24.1 3 17.6
Moderate, n = 64 22 40.7 9 28.1 21 72.4 12 70.6
Low, n = 30 14 26.0 13 40.6 1 3.5 2 11.8
The significant priority of moderate grade of tumor 
differentiation was determined in luminal A (40.7%), 
basal (72.4%) and Her2/neu-positive (70.6%) subtypes, 
and only in luminal B subtype the low grade of tumor dif-
ferentiation (40.6%) prevailed. These data evidenced the 
intertumoral heterogeneity of BC both by clinical indices 
and by pathomorphological tumor features.
Immunohistochemical study of CSC markers ex-
pression in surgical material detected their expression 
in 34 (25.4%) BC patients, who had different molecu-
lar subtypes. Distribution of this marker expression 
within each molecular subtype (Table 3) showed that 
frequency of expression varied: the highest num-
ber of tumors with of CSC markers expression was 
among the patients with luminal B and basal subtypes 
(28.1 and 44.8%, respectively), while in patients with 
luminal A and Her2/neu-positive subtypes it was 
lower (16.6 and 17.6%, respectively). The highest 
frequency of cells with CSC marker expression was 
revealed in BC patients with basal molecular subtype. 
The prevalence of cells with CSC markers depend-
ing on cells’ molecular phenotype was confirmed 
by Pearson coefficient mutual conjugation (c = 0.54). 
This indicates the existing of moderate correlation 
of frequency of cells with CSC markers with tumor 
molecular subtype (р < 0.05).
Table 3. Prevalence of tumors with CSC markers expression in BC pa-
tients with different molecular subtypes
Molecular subtype of BC
BC patients with ex-
pression of CSC 
marker 
CD44+/CD24−
n %
Luminal А: ER+PR+Hеr2/neu−, n = 54 (100%) 9 16.6
Luminal B: ER+PR+Hеr2/neu+, n = 32 (100%) 9 28.1
Basal: ER−PR−Hеr2/neu−, n = 29 (100%) 13 44.8
Hеr2/neu-positive: ER−PR−Hеr2/neu+, n = 17 (100%) 3 17.6
Among criteria, which have essential clinical sig-
nificance for prognosis evaluation and conduction 
adequate therapy of BC patients, the stage of tumor 
process is crucial.
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The majority of BC patients with CD44+/CD24− 
phenotype had BC I stage (34.3%). Statistic analy-
sis showed that Yule association coefficient was 
0.28 (р > 0.05), which underlines poor correlation 
between tumor process stage and number of tumors 
with positive CSC markers expression (Table 4).
Table 4. Distribution of tumors with CSC marker CD44+/CD24− expres-
sion in BC patients with I–II stage
Characteristic 
of patients
Tumors with expression of CSC marker CD44+/CD24-
n %
Stage І, n = 35 12 34.3
Stage ІІ, n = 97 22 22.7
Taking into account literature data on pos-
sible impact of CSC expression in primary tumor and 
higher proliferative, invasive and metastatic potential 
of tumors, it was of certain interest to study the cor-
relation between frequency of tumors with CD44+/
CD24− markers in patients with or without regional 
metastases. Among total number of patients with-
out metastases the CD44+/CD24− markers was 
observed in 7 (7.4%) cases, while among those with 
metastases such phenotype was detected more of-
ten — in 27 (72.9%) cases (Table 5). Statistic analysis 
showed high correlation between the presence of cells 
with CSC markers expression and BC metastases 
in regional lymph nodes (Yule association coefficient: 
0.943; р < 0.05).
Table 5. Distribution of tumors with CSC marker CD44+/CD24− expres-
sion in BC patients without metastases and with regional metastases
Characteristic of patients
Tumors with expression of CSC 
marker CD44+/CD24−
n %
No metastases, (N0), n = 95 (100%) 7 7.4
Metastases in regional lymph nodes 
(N1–3), n = 37 (100%) 27 72.9*
Notes: *р < 0.05 compared to group of patients without metastasis.
In clinical studies the significance of BC differen-
tiation grade for clinical course of disease was evi-
denced. For this reason, further analysis of obtained 
results of immunohistochemical study was devoted 
to comparison of CD44+/CD24- expression in BC with 
different tumor differentiation (Table 6). The analysis 
of distribution of tumors with phenotype CD44+/
CD24− showed that in group of patients with high and 
moderate tumor differentiation the amount of such 
tumors was lower (18.4 and 25.0%, respectively) than 
in patients with low differentiation (36.7%). Statistic 
processing detected poor correlation between tumor 
differentiation grade and expression of CSC markers 
(Pearson coefficient c = 0.3; р > 0.05).
Table 6. Distribution of tumors with CSC marker CD44+/CD24- expres-
sion in BC of different differentiation grade
BC differentiation grade Number of tumors with phenotype CD44+/CD24−n %
High, n = 38 (100%) 7 18.4
Moderate, n = 64 (100%) 16 25.0
Low, n = 30 (100%) 11 36.7
Taking into account obtained results, which are 
characterized by variability of molecular subtypes 
in BC patients and CSC markers expression, it was 
important to evaluate significance of the latter as cri-
teria of patients’ overall survival. Fig. 2 shows curves 
of overall survival of BC patients with different molecu-
lar subtypes depending on presence or lack of tumor 
cells with CSC markers. As it could be seen from 
presented data, survival of patients with basal BC was 
significantly higher at lack of the cells with phenotype 
CD44+/CD24− in tumors and, correspondingly, lower 
at presence of such cells (р < 0.05). In patients with 
BC of luminal (A and B) and HER-2-positive subtypes, 
significant changes in survival depending on CSC 
markers expression were not found (р > 0.05).
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Fig. 2. Overall survival of BC patients with different molecular sub-
types depending on presence or lack of SCS markers in tumor cells
In order to determine the significance of using 
CSC markers CD44+/CD24− in clinical practice, Cox 
regression analysis was carried out. Its results suggest 
the possibility of using this index (phenotype of CSC 
CD44+/CD24−) as marker for prediction of individual 
prognosis for patients with basal BC (Table 7).
Table 7. Results of Cox regression analysis
Marker Molecular subtype β p
CD44+/CD24− Luminal А −0.11 > 0.05
Luminal B −0.21 > 0.05
HER-2/neu-positive 0.17 > 0.05
Basal (triple negative) 0.57 < 0.05
Thus, obtained results show that BC is character-
ized by heterogeneity by not only tumors’ morphology, 
but also by molecular subtypes and by CSC markers 
expression (CD44+/CD24−). Genetic heterogeneity 
of invasive forms of BC is reflected in wide range of his-
tological types, various tumor differentiation grade and 
variability of disease clinical course. As it is known, the 
luminal subtype A is referred to the low-aggressive 
tumors with favorable prognosis; on the contrary, the 
luminal B subtype is characterized by aggressiveness 
and worse prognosis. Other subtypes — HER2-positive 
and triple negative (basal subtype) — are referred 
to the tumors with worse prognosis of survival, though 
in the first one the HER2/neu expression occurs, while 
in the latter no changes of this cancer oncogene were 
detected. At the same time, exactly the basal sub-
type is characterized by the worst patients’ survival 
rates. It can be suggested that in aggressive course 
of BC of basal subtype the particular role is played 
by cells with CSC phenotype CD44+/CD24−. In the 
relationship “CSC and cancer” many unsolved ques-
tions remain. For this reason, CSC origin, their evolu-
tion, role of such molecular markers as CD44 and 
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CD24 in different stages of tumor genesis are under 
wide discussion [12, 26–28].
Population of CSC is not large as compared with 
general population of cells in tumor, but it can seri-
ously impact biological properties of BC. The fol-
lowing literature data confirm this. In BC patients the 
connection between expression of cells with CD44+/
CD24− and aggressive clinical course and metastasis 
was determined [29, 30]. The disseminated cells with 
CD44+/CD24− markers appear already at the early 
stage of tumor genesis in mammary gland [31]. 
The correlation between CSC CD44+/CD24− and the 
epidermal growth factor receptor (EGFR) in invasive 
variant of ductal carcinoma, which can favor higher 
proliferation of tumor cells, was found. Increase of pro-
portion of cells with phenotype CD44+/CD24−/low 
is significant for manifestations of BC aggressiveness 
and increased metastasis risk [32]. There are signs 
that tumor cells with mentioned phenotype play cer-
tain role not only in activation of metastasis, but also 
in formation of resistance to cytostatic drugs [33]. 
Subpopulations of cells with CSC phenotype are rela-
tively more radioresistant, so it can be associated with 
development of relapses after radiotherapy [34]. One 
more important fact is the lack of correlation between 
cells with phenotype CD44+/CD24− and response 
to hormone therapy in patients with receptor-positive 
forms of BC [35].
At the same time, it was determined that fraction 
of tumor cells CD44+/CD24−/low is quite flexible and 
depends on many factors, including signals of micro-
environment. For example, under hypoxia of tumors 
in cancer patients with CSC phenotype CD44+/CD24−/
low, the prognosis is significantly worse. Some authors 
noticed the changes of CD44+ and CD24- expressions 
in metastases as compared with primary tumor [36]. 
We also confirmed this fact in immunohistochemi-
cal study of CD44s expression in primary tumors 
and implanted metastases of serous ovary cancer. 
It was found that changes of this marker expression 
in implanted metastases had different tendencies: only 
in 26.7% of patients CD44s expression did not change, 
while the number of CD44s-positive cells increased 
in 46.6% cases and in 26.7% cases decreased [37]. 
These changes underline the individual nature of in-
tercellular adhesion molecule expression in implanted 
metastases that can be the evidence of clonal nature 
of metastasis or changes on the level of tumor-host 
(metabolic, hormonal etc.). If we take into account 
the study of M. Shi pitsin et al. [38], the relations be-
tween cells with different phenotype in tumor popula-
tion are depended on their differentiation response 
to the activation of TGF-β signal pathway.
Obtained results demonstrate multiple functions 
of CSC and their connection with unequal manifes-
tations of BC aggressiveness of different molecular 
subtypes. Undoubtedly, the role of CSC in BC, as well 
as in tumors of other genesis, their association with 
patients’ hormonal status, peculiarities of microenviron-
ment and other important functions of these cells are 
not fully identified. At the same time, despite existing 
disputable issues, CSC may be considered as very 
interesting for active future studies of the role of these 
cells at different stages of tumor genesis. It is important 
for understanding the molecular mechanisms of forma-
tion of different molecular BC subtypes, as well as for 
study of possibilities of using CSC as individual mark-
ers of tumors’ malignancy and disease clinical course, 
as well as for clarified personalized treatment.
CONCLUSION
Within the luminal A and B, triple negative and HER2-
positive molecular phenotypes of BC the differences 
in frequency of cells with CSC markers CD44+/CD24− 
were determined. The highest amount of such cells 
was observed in BC patients with triple negative (basal) 
subtype that can be the cause of its aggressive clinical 
course. Correlation between expression of such cells 
and presence of metastases in regional lymph nodes 
was determined. Difference in overall survival of patients 
with BC of basal and molecular subtype depending 
on expression in tumor cells of markers of stem cancer 
cells CD44+/CD24− was detected.
Detection of tumor cells with markers CD44+/
CD24− within BC molecular subtypes may be addition-
al criterion for the advanced biological characteristic 
of BC, and in BC patients with basal molecular sub-
type — for predictive evaluation of individual potential 
of tumors to aggressive clinical course.
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